CAJ | 학술논문

目的：研究大蒜素对IgA肾病肾间质纤维化的影响,并探讨其可能的肾脏保护机制。方法联合IgA肾病模型及单侧输尿管结扎的方法建立IgA肾病纤维化的动物模型。将SD大鼠随机分为正常对照组、模型对照组及高、低剂量大蒜素治疗组,按各组相应药物剂量灌胃。于干预前、干预14天及28天检测各组大鼠尿红细胞计数、尿素氮水平及血清肿瘤坏死因子-α( TNF-α)、α-平滑肌肌动蛋白(α-SMA)含量；并于28天末光镜下观察各组大鼠肾脏的病理改变。结果与模型对照组相比,高、低剂量大蒜素治疗组大鼠尿红细胞计数(模型组-高剂量组,干预14天/28天,t=1.12/5.58；模型组-低剂量组,干预14天/28天,t=1.62/7.51)、尿素氮水平、血清TNF-α(模型组-高剂量组,干预14天/28天,t=3.48/11.95；模型组-低剂量组,干预14天/28天,t=4.76/12.78)、α-SMA含量(模型组-低剂量组,干预14天/28天,t=5.38/5.77)均降低(均P<0.05),肾小球系膜区IgA沉积强度明显减轻,肾组织病理纤维化程度亦有所减轻。大蒜素高、低剂量治疗组在降低尿红细胞计数(干预28天, t=1.99)、血清TNF-α(干预28天,t=3.73)和α-SMA(干预14天/28天,t=5.60/4.81)水平上差异均有统计学意义(均P<0.05),以大蒜素低剂量效果稍好。结论血清TNF-α和α-SMA在IgA肾病纤维化进展中进行性增高；大蒜素能够改善IgA肾病纤维化大鼠的临床症状、减轻肾脏病理学损害,可能通过降低血清TNF-α和α-SMA水平发挥抗肾脏纤维化的作用。
목적：연구대산소대IgA신병신간질섬유화적영향,병탐토기가능적신장보호궤제。방법연합IgA신병모형급단측수뇨관결찰적방법건립IgA신병섬유화적동물모형。장SD대서수궤분위정상대조조、모형대조조급고、저제량대산소치료조,안각조상응약물제량관위。우간예전、간예14천급28천검측각조대서뇨홍세포계수、뇨소담수평급혈청종류배사인자-α( TNF-α)、α-평활기기동단백(α-SMA)함량；병우28천말광경하관찰각조대서신장적병리개변。결과여모형대조조상비,고、저제량대산소치료조대서뇨홍세포계수(모형조-고제량조,간예14천/28천,t=1.12/5.58；모형조-저제량조,간예14천/28천,t=1.62/7.51)、뇨소담수평、혈청TNF-α(모형조-고제량조,간예14천/28천,t=3.48/11.95；모형조-저제량조,간예14천/28천,t=4.76/12.78)、α-SMA함량(모형조-저제량조,간예14천/28천,t=5.38/5.77)균강저(균P<0.05),신소구계막구IgA침적강도명현감경,신조직병리섬유화정도역유소감경。대산소고、저제량치료조재강저뇨홍세포계수(간예28천, t=1.99)、혈청TNF-α(간예28천,t=3.73)화α-SMA(간예14천/28천,t=5.60/4.81)수평상차이균유통계학의의(균P<0.05),이대산소저제량효과초호。결론혈청TNF-α화α-SMA재IgA신병섬유화진전중진행성증고；대산소능구개선IgA신병섬유화대서적림상증상、감경신장병이학손해,가능통과강저혈청TNF-α화α-SMA수평발휘항신장섬유화적작용。
Objective To study the influence of diallyl trisulfide on IgA nephropathy renal interstitial fibrosis and to explore its possible renal protective mechanism. Methods IgA nephropathy fibrotic model in rats were established in study by combining IgA nephropathy model with unilateral ureteral obstruction. The healthy SD rats were randomly and equally divided into 4 groups: normal control group, model control group, high-dose dially trisulfide ( DATS) treatment group and low-dose DATS treatment group. The above groups were lavaged with corresponding drug. The urine and blood of rats were examined for urinary red blood cell count, blood urea nitrogen, TNF-αand α-SMA before intervention, 14 and 28 days after intervention. At the 28th day, all rats were sacrificed and their pathomorphological changes in kidneys were observed by immune fluorescence microscope. Results Compared with model control group, the levels of urine erythrocyte (model control group —high-dose DATS treatment group, at 14/28 days after intervention,t =1. 12/5. 58; model control group— low-dose DATS treatment group, at 14/28 days after intervention, t=1. 62/7. 51), blood urea nitrogen, TNF-α (model control group—high-dose DATS treatment group, at 14/28 days after intervention, t =3. 48/11. 95; model control group —low-dose DATS treatment group, at 14/28 days after intervention,t=4. 76/12. 78) andα-SMA (model control group—low-dose DATS treatment group, at 14/28 days after intervention,t=5. 38/5. 77) reduced in both DATS treatment groups. The degree of IgA deposits at glomerular mesangial area and the renal pathological fibrosis relieved in both DATS treatment groups. There were significant differences between high-dose and low-dose DATS treatment groups in reducing the levels of urine erythrocyte (at 28 days after intervention,t=1. 99), TNF-α (at 28 days after intervention,t=3. 73) and α-SMA (at 14/28 days after intervention,t=5. 60/4. 81) (all P<0. 05). The effect of low-dose DATS treatment was more obvious. Conclusion The levels of TNF-α and α-SMA increase progressively in IgA nephropathy fibrosis developing. The dially trisulfide can relieve the clinical symptoms and pathological damages in IgA nephropathy fibrotic rats, and can prevent the occurrence of renal interstitial fibrosis by reducing the levels of serum TNF-α and α-SMA.